Transdermal nicotine and Down's syndrome
This article was originally published in The Tan Sheet
Executive Summary
Cognitive improvements were found in five retarded individuals subjected to auditory response tests after being given 5 mg of transdermal nicotine for two hours, University of Austria, Vienna researchers report in the Oct. 21 Lancet. The study, conducted by Rainer Seidl, MD, et al., found "improvements possibly related to attention and information processing" in a group of five 18-34 year old patients with Down's syndrome in relation to controls. Seidl et al. note due to the small study size, results cannot be generalized, and the effects of higher nicotine doses are not known. Nicotine patches were provided by Pharmacia
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning